Evidence map›Paper›PMID 40799614›Full record

ArticlebioRxiv : the preprint server for biology2025

Free energy and flexibility analysis of autoinhibited human BRAF.

Jeremy O B Tempkin, Fikret Aydin, Sebnem Essiz, Yue Yang, Timothy S Carpenter, David E Durrant, Deborah K Morrison, Helgi I Ingólfsson, Frederick H Streitz, Dwight V Nissely and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Jeremy O B TempkinPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Fikret AydinPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Sebnem EssizMolecular Biology and Genetics, Department of Engineering and Natural Sciences, Kadir Has University, Fatih 34083, Istanbul, Turkey.
Yue YangPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Timothy S CarpenterPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
David E DurrantLaboratory of Cell and Developmental Signaling, Center for Cancer Research (CCR), National Cancer Institute (NCI), Frederick, MD 21702, USA.
Deborah K MorrisonLaboratory of Cell and Developmental Signaling, Center for Cancer Research (CCR), National Cancer Institute (NCI), Frederick, MD 21702, USA.
Helgi I IngólfssonPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Frederick H StreitzComputing Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Dwight V NisselyNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
Felice C LightstonePhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Xiaohua ZhangPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

The RAF serine/threonine protein kinases function as direct effectors of RAS in the intracellular transmission of extracellular growth signals, and they are key targets for drug discovery given the high incidence of oncogenic mutations in RAF and other components of this signaling pathway. In its inactive state, RAF is held in an autoinhibited conformation in the cytosol through a combination of intramolecular interactions and binding to a regulatory 14-3-3 protein dimer. Activation of RAF is initiated by its interaction with membrane-localized, GTP-bound RAS, which induces conformational changes that release RAF from its autoinhibited state. However, the molecular mechanisms governing RAF activation remain incomplete, largely due to the challenges in experimentally capturing intermediate conformational states in this process. To address this gap, we developed a comprehensive all-atom model of BRAF based on existing cryo-EM structures. Using this model, we performed extensive molecular dynamics simulations to evaluate the stability and free energy landscape of autoinhibited BRAF in solution. Our analysis reveals conformational flexibility within the autoinhibited complex, suggesting that this dynamic behavior may play a role in facilitating BRAF activation upon engagement with membrane-bound RAS.

Indexed as

14–3-3 proteinconformational changemolecular dynamicsRAF kinasethermodynamics

Identifiers

PMID40799614
PMCPMC12340820

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.